HC Wainwright Issues Pessimistic Outlook for PLX Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – HC Wainwright cut their Q2 2026 earnings per share estimates for Protalix BioTherapeutics in a research note issued to investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.27. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q3 2026 earnings at $0.01 EPS and FY2026 earnings at $0.25 EPS.

Protalix BioTherapeutics Price Performance

Shares of PLX stock opened at $2.12 on Thursday. Protalix BioTherapeutics has a 1-year low of $1.32 and a 1-year high of $3.19. The stock’s 50-day moving average is $2.14 and its 200 day moving average is $2.20. The company has a market cap of $170.81 million, a P/E ratio of -16.31 and a beta of -0.01.

Institutional Investors Weigh In On Protalix BioTherapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its position in Protalix BioTherapeutics by 70.6% during the first quarter. Bank of America Corp DE now owns 79,079 shares of the company’s stock valued at $172,000 after purchasing an additional 32,727 shares in the last quarter. Lazard Asset Management LLC boosted its position in Protalix BioTherapeutics by 21.3% during the first quarter. Lazard Asset Management LLC now owns 86,617 shares of the company’s stock valued at $188,000 after purchasing an additional 15,224 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Protalix BioTherapeutics by 932.7% during the first quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock valued at $644,000 after purchasing an additional 268,099 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Protalix BioTherapeutics by 4.0% during the first quarter. Bank of New York Mellon Corp now owns 219,307 shares of the company’s stock valued at $476,000 after purchasing an additional 8,440 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Protalix BioTherapeutics by 12.4% during the fourth quarter. Invesco Ltd. now owns 50,563 shares of the company’s stock valued at $91,000 after purchasing an additional 5,560 shares in the last quarter. Institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.